LUBBOCK, Texas, Feb. 21, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 16, 2012, MIT, received its first shipment of strontium-82(Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France.
This historic event marks the first shipment of Sr-82 to be received by a private, non-government, entity in the U.S. in support of Sr-82 production. The receipt of this material also marks the beginning of MIT's validation efforts in order to qualify Sr-82 product material as Active Pharmaceutical Ingredient (API).
Over the next six months MIT will continue to obtain Sr-82 target solutions, from foreign irradiators at the facility in Lubbock, Texas. MIT will conduct the critical processing procedures for final purification into API grade Sr-82. Validation of the API grade Sr-82 product material is key to the Positron/MIT 2012 Drug Master File submission to the U.S. FDA.
"With the receipt of Sr-82 from ARRONAX, Positron and MIT have achieved an incredible milestone," states MIT President and Positron Pharmaceutical, Chief Technical Officer, Jason Kitten. "Up until this point in time, the Department of Energy was the only organization in the United States capable of processing Sr-82 material. By executing our plans, MIT is well positioned to meet the Drug Master File qualifications, which will further advance and accelerate Positron's Sr-82 mission. Positron continues its progress and is on schedule to meet 2012 Sr-82 supply objectives. Positron's goal of solidifying and advancing cardiac PET's progression in the U.S. is well underway."
Positron Corporation is a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services
|SOURCE Positron Corporation|
Copyright©2010 PR Newswire.
All rights reserved